| Literature DB >> 17368037 |
Cesare Gridelli1, Matti S Aapro, Sandro Barni, Giordano Domenico Beretta, Giuseppe Colucci, Bruno Daniele, Lucia Del Mastro, Massimo Di Maio, Luigi De Petris, Francesco Perrone, Nick Thatcher, Filippo De Marinis.
Abstract
Febrile neutropenia is a relatively frequent event in cancer patients treated with chemotherapy. A relevant body of scientific evidence has been produced in the last 2 decades, through clinical trials addressing the efficacy of colony stimulating factors (CSFs) in the prevention and treatment of febrile neutropenia. The correct use of CSFs needs to be optimized, and several guidelines have been produced and periodically updated, in order to uniform and guide clinical practice. The aim of this review is to synthesize the most relevant clinical trials and the most important existing guidelines about the role of CSFs in solid tumours. Role of CSFs as primary prophylaxis, secondary prophylaxis and treatment of afebrile and febrile neutropenia is discussed. A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17368037 DOI： 10.1016/j.critrevonc.2007.01.008
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312